



Legislation Text

File #: 23-1663, Version: 1

**Contract Request Template (Contracts; IGAs; Leases)**

**Date Submitted: 11-6-2023**

**Requesting Agency: DDPHE**  
**Division:**

**Subject Matter Expert Name: Will Fenton**  
**Email Address:**  
**Phone Number:**

**Item Title & Description:**

*(Do not delete the following instructions)*

*These appear on the Council meeting agenda. Initially, the requesting agency will enter a 2-3 sentence description. Upon bill filling, the City Attorney's Office should enter the title above the description (the title should be in **bold** font).*

*Both the title and description must be entered between the red "title" and "body" below. Do **not** at any time delete the red "title" or "body" markers from this template.*

**A resolution approving and providing for the execution of a proposed Grant Agreement between the City and County of Denver and the United States Center for Disease Control and Prevention concerning the "Overdose Data to Action (OD2A: LOCAL) Grant" program and the funding therefor.**

Approves a grant agreement with the Centers for Disease Control and Prevention for \$1,807,494 and an end term of 8-31-2024 to expand overdose prevention efforts including harm reduction work, linkage to care services, stigma reduction efforts, drugs testing capacities, and collaboration among healthcare providers, citywide. ENVHL-202370069. The last regularly scheduled Council meeting within the 30-day review period is on 12-11-2023. The Committee approved filing this item at its meeting on 11-8-2023.

**Affected Council District(s) or citywide?**

**Citywide**

**Contract Control Number:**  
**ENVHL-202370069**

**Vendor/Contractor Name (including any "DBA"):**

**Centers for Disease Control and Prevention**

**Type and Scope of services to be performed:**

In alignment with the OD2A: LOCAL priorities dictated by the CDC (fiscal sponsor), DDPHE's OD2A: Denver emphasizes linkage

to and retention in care, strong community-based partnerships, access to harm reduction, building and improving overdose surveillance infrastructure and tracking, and addressing emerging drug threats. All activities below outlined are carried out primarily by community-based partners with the support of DDPHE with funds, training, and additional resources required. DDPHE staff dedicated to this grant will work alongside partners in developing all 6 strategies outlined here.

1A: Linkage to and Retention in Care. For this strategy, the main activities include utilizing navigators to connect people to services, initiating long-term care (LTC) activities, supporting retention in care, maintaining recovery, and supporting re-engagement in care.

2A: Harm Reduction. The main activities consist of implementing strategies that increase TX entry, reduce drug use frequency and high-risk drug use practices, and improve the overall health of PWUD with a focus on reducing overdose. 3A: Stigma Reduction. Main activities include addressing stigma among different audiences, such as individuals with SUD, public safety, healthcare systems, and the public, across community, health care, and public safety settings

3A: Stigma Reduction. Main activities include addressing stigma among different audiences, such as individuals with SUD, public safety, healthcare systems, and the public, across community, health care, and public safety settings.

4A: Clinician & Health System Best Practices. The main activities for the Clinician & Health System Best Practices include improving the clinical management of pain and SUD, and building healthcare infrastructure to improve care coordination with a focus on providing guideline-concordant care to reduce overdose.

6A: Overdose Surveillance Infrastructure. The main activities for this component aim to improve and enhance overall capacity to conduct overdose-related surveillance and include creating more timely and actionable data outputs and increasing data sharing.

Component B: Drug Product and/or Paraphernalia Testing. The main activities for this component involve using CDC guidance to conduct laboratory toxicologic testing of drug products and/or drug paraphernalia to track the lethality of the illicit drug market.

All contractors will participate in quarterly meetings and meet goals specific to their select strategies associated with OD2A:Denver.

**Location (if applicable):**

**WBE/MBE/DBE goals that were applied, if applicable (construction, design, Airport concession contracts):**

**Are WBE/MBE/DBE goals met (if applicable)?**

N/A

**Is the contract new/a renewal/extension or amendment?**

New

**Was this contractor selected by competitive process or sole source?**

N/A

**For New contracts**

**Term of initial contract:**

**9-1-2023 through 8-31-2024**

**Options for Renewal:**

**How many renewals (i.e. up to 2 renewals)?**

**Term of any renewals (i.e. 1 year each):**

**Cost of initial contract term:**

**\$1,807,494**

**Cost of any renewals:**

**Total contract value council is approving if all renewals exercised:**

**For Amendments/Renewals Extensions:**

**Is this a change to cost/pricing; length of term; terms unrelated to time or price (List all that apply)?**

***If length changing***

**What was the length of the term of the original contract?**

**What is the length of the extension/renewal?**

**What is the revised total term of the contract?**

***If cost changing***

**What was the original value of the entire contract prior to this proposed change?**

**What is the value of the proposed change?**

**What is the new/revised total value including change?**

***If terms changing***

**Describe the change and the reason for it (i.e. compliance with state law, different way of doing business etc.)**